Topical Thymoquinone in Psoriasis Vulgaris

ConditionPsoriasis Vulgaris

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-60

SponsorAssiut University

About this trial

A previous trial found that N. sativa oil was more effective as an antipsoriatic agent, particularly when taken as both a cream and a pill. This confirmed that N. sativa possesses antipsoriatic properties and can alleviate psoriasis symptoms

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with clinical diagnosis of mild psoriasis vulgaris

Age: between 18 and 60 years' old

Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment

Disqualifiers

Psoriasis vulgaris involving > 10% of the body surface area, pustular or erythrodermic psoriasis.

Pregnant or lactating females.

Patients with any current dermatological disease.

Patients with any current systemic disease.

Trial design

Design model

Single group

Treatments tested in this trial

Topical thymoquinone Ointment
Drug
One plaque per patient on one side of the body will be selected, whose diameter would not exceed 5-10 cm2 to apply Thymoquinone ointment as a monotherapeutic ttt twice daily for 3 months.
topical placebo ointment
Drug
In each patient a single similar psoriatic plaque on the other side of the body \[as regard anatomical site, size and TES (thickness, erythema, scales) score\] will be treated with placebo ointment twice daily for 3 months as a control.

Treatment groups

30 Participants

are divided into 2 treatment groups

Group A: topical thymoquinone ointmentExperimental treatment 1 intervention

Group B: topical placebo ointmentPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

Psoriasis severity score (TES) assessment

Psoriasis severity score (TES): It is a physician-based, four-point scoring system in which the thickness, erythema, and scales within each plaque will be rated from 0 (none) to 3 (severe)at baseline and to evaluate the therapeutic outcome of topical thymoquinone ointment in each follow up visit.

Time frame

3 months

Secondary outcomes

Evaluation of treatment adverse effects

Any local or systemic side effects will be reported to evaluate the safety of Thymoquinone ointment for treatment of localized plaque psoriasis

Time frame

3 months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: